Shares of Medivation (MDVN) Drops by -0.35%

Medivation (MDVN) has risen sharply, recording gains of 4.3% in the past 4 weeks. However, the stock has corrected -0.35% in the past 1 week, providing a good buying opportunity on dips. Medivation (MDVN) : During the past 4 weeks, traders have been relatively bearish on Medivation (MDVN), hence the stock is down -0.07% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.82% relative to the S&P 500. The stock has recorded a 20-day Moving Average of 2.74% and the 50-Day Moving Average is 2.36%.

Medivation (NASDAQ:MDVN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $61.66 and $61.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $61.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $61.88, notching a gain of 0.23% for the day. The total traded volume was 1,886,852 . The stock had closed at $61.74 on the previous day.


The company Insiders own 3.54% of Medivation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.41% . Institutional Investors own 90.66% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of 0.89%. In a related news,The officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., Powell Andrew Kenneth William sold 2,578 shares at $60.42 on June 6, 2016. The Insider selling transaction had a total value worth of $155,763. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.